ROLVEDON
Chemotherapy-induced Neutropenia
ApprovedMarketed
Key Facts
About Assertio Holdings
Assertio Holdings is a NASDAQ-listed commercial biotech focused on acquiring and maximizing established pharmaceutical products in neurology, pain management, and hospital care. Its strategy centers on a lean commercial model, targeting non-promoted or under-valued brands for strategic marketing and lifecycle extensions. Recent years have seen significant corporate transformation, including portfolio divestitures and a name change, to sharpen focus on its core therapeutic areas and return to profitability.
View full company profileTherapeutic Areas
Other Chemotherapy-induced Neutropenia Drugs
| Drug | Company | Phase |
|---|---|---|
| BBT-015 | Bolder Biotechnology | Preclinical |
| Bmab 1100 (Pegfilgrastim biosimilar) | Biocon | Approved |
| Ziextenzo (pegfilgrastim) | Sandoz Group | Marketed |
| Biosimilar Pegfilgrastim | Viatris | Launched |
| UDENYCA (pegfilgrastim-cbqv) | Coherus BioSciences | Approved |